From rodent cages to Medicare claims: GLP-1 drugs and opioid use disorder

Despite at least three FDA-approved medications for opioid use disorder, deaths from opioid overdose remain, in the words of a review published this month in Biological Psychiatry, "unacceptably high" — a gap driving interest in whether GLP-1 receptor agonists, already reshaping obesity and diabetes treatment, might offer a new option [s1]. The review lays out the full evidence chain currently available, from rodent studies through early human data.

What the animal research shows

In preclinical studies, acute administration of exendin-4 and the longer-acting drugs liraglutide, semaglutide, tirzepatide, and other dual and triple agonists reduced opioid taking and opioid-seeking behavior — whether that seeking was triggered by drug-related cues, the opioid itself, or stress [s1]. Chronic treatment with GLP-1 receptor agonists also reduced responding for opioids in these models, though the review notes an important caveat: tolerance developed with chronic administration of higher GLP-1 receptor agonist doses, meaning the drugs' effect diminished somewhat with sustained high-dose use in the animal studies reviewed [s1].

What the human evidence shows so far

Human data remains considerably thinner than the animal evidence. One small clinical trial found a 40% reduction in opioid craving following treatment with liraglutide [s1] — a single trial, and the review doesn't report its exact sample size, but it represents the first controlled human signal supporting the mechanism suggested by the animal data. Three additional clinical trials are currently ongoing: two testing semaglutide and one testing tirzepatide, each as an adjunctive treatment alongside buprenorphine or methadone — the existing standard medications for opioid use disorder, rather than as standalone replacements for them [s1].

Ahead of those trials completing, researchers have turned to large real-world datasets — electronic health records, the TriNetX database, and Medicare claims — and found a 40% reduction in both opioid overdose and hospital admissions for opioid use disorder among patients treated with a GLP-1 receptor agonist or a GLP-1/GIP dual agonist for type 2 diabetes and/or obesity [s1].

Why the review frames this evidence chain carefully, rather than as settled

This review's real value lies in how explicitly it separates what's established from what's still preliminary: robust preclinical evidence, a single small human trial, and observational associations from real-world data — each a meaningfully different tier of evidence, and none yet equivalent to a dedicated, adequately powered randomized controlled trial testing GLP-1 drugs specifically for opioid use disorder. The real-world data showing a 40% reduction in overdose and hospitalization is observational, drawn from people who were prescribed GLP-1 drugs for diabetes or obesity rather than for opioid use disorder specifically — meaning it can't rule out that people prescribed and adherent to a GLP-1 drug differ systematically, in ways relevant to overdose risk, from those who weren't.

The tolerance finding in animal studies is a caution worth flagging

The review's mention that tolerance developed with chronic higher-dose GLP-1 receptor agonist treatment in animal models [s1] is a detail easy to skip past in favor of the more dramatic top-line reduction numbers, but it's directly relevant to how any eventual human treatment protocol might need to be designed — if a similar tolerance pattern emerged in humans on sustained, high-dose GLP-1 therapy, it could limit the durability of any protective effect against opioid use, a question none of the currently described human evidence yet addresses directly.

Why testing GLP-1 drugs as adjunctive, not standalone, treatment matters

All three of the ongoing human trials described test GLP-1 drugs as an addition to existing standard-of-care opioid use disorder medications (buprenorphine or methadone), not as a replacement for them [s1] — a design choice reflecting that buprenorphine and methadone remain the evidence-backed foundation of opioid use disorder treatment, with GLP-1 drugs being tested as a potential complement rather than an alternative.

What this doesn't establish

This is a narrative review synthesizing existing evidence, not a new experiment — it doesn't add primary data beyond what its cited sources already show, and none of the underlying human evidence described (one small trial, several observational analyses) rises to the level of a definitive, adequately powered randomized trial specifically testing GLP-1 drugs for opioid use disorder as a primary outcome. The review's own conclusion is appropriately hedged: it states these findings "suggest that GLP-1RAs hold promise" while explicitly noting "additional clinical trials are needed" [s1].

What to watch

Results from the three ongoing clinical trials testing semaglutide and tirzepatide as adjunctive opioid use disorder treatments, which will provide the first dedicated, purpose-built human evidence for this specific question. GLP-1 receptor agonists are not approved for opioid use disorder; this article is not medical advice.

Sources

1. Glucagon-Like Peptide-1 Receptor Agonists as a Candidate Treatment for Opioid Use Disorder: From Rats to Humans — Biological Psychiatry, 21 July 2026